AnaptysBio (ANAB) director receives 5,500 options and 4,000 RSUs

Rhea-AI Filing Summary

AnaptysBio director Magda Marquet reported new equity awards from the company. On January 6, 2026, she received a stock option to buy 5,500 shares of AnaptysBio common stock at an exercise price of $43.91 per share. This option vests in equal 1/12 installments each month starting on February 6, 2026, as long as she continues providing service to the company on each vesting date.

On the same date, she was also granted 4,000 restricted stock units (RSUs), each representing the right to receive one share of common stock for no cash consideration upon settlement. These RSUs vest as to 100% of the total award on the date of AnaptysBio’s 2027 annual meeting of shareholders, contingent on her continued service through that date.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Marquet Magda

(Last) (First) (Middle)

C/O ANAPTYSBIO, INC.

10770 WATERIDGE CIRCLE, SUITE 210

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ANAPTYSBIO, INC [ ANAB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/06/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$43.91	01/06/2026		A		5,500		(1)	01/05/2036	Common Stock	5,500	$0	5,500	D
Restricted Stock Unit	(2)	01/06/2026		A		4,000		(3)	(3)	Common Stock	4,000	$0	4,000	D

Explanation of Responses:

1. The stock option vests as to 1/12 of the total shares monthly commencing on Februray 6, 2026 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

2. Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.

3. The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2027 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

	/s/ Eric Loumeau, Attorney-in-Fact	01/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did AnaptysBio (ANAB) director Magda Marquet report?

Magda Marquet reported two equity awards dated January 6, 2026: a stock option for 5,500 shares of AnaptysBio common stock at an exercise price of $43.91 per share, and a grant of 4,000 restricted stock units (RSUs) that each convert into one share for no cash payment upon settlement.

How do Magda Marquet’s new AnaptysBio stock options vest?

The stock option covering 5,500 shares vests in 1/12 installments monthly, beginning on February 6, 2026. Each monthly vesting requires that she continue to provide service to AnaptysBio on the applicable vesting date until the option is fully vested.

What are the terms of the 4,000 RSUs granted to Magda Marquet by AnaptysBio?

Each of the 4,000 RSUs represents a contingent right to receive 1 share of AnaptysBio common stock upon settlement for no consideration. The RSUs vest as to 100% of the award on the date of AnaptysBio’s 2027 annual meeting of shareholders, subject to her continued service.

Are Magda Marquet’s new AnaptysBio equity awards held directly or indirectly?

The Form 4 shows the 5,500 stock options and 4,000 RSUs as direct (D) ownership. No indirect ownership entity or special nature of indirect beneficial ownership is indicated in the filing.

Does Magda Marquet pay cash for the AnaptysBio RSUs or option grant?

The stock option has an exercise price of $43.91 per share that would be paid upon exercise. The 4,000 RSUs each convert into one share of common stock upon settlement for no consideration, meaning no cash payment is required at settlement.